0.432

7.22% -0.0336

After Hours: .43 -0.002 -0.46%

Vivos Therapeutics Inc (VVOS)

Overview News Price History Financials Discussions Forecast Stock Split

Vivos Therapeutics Inc stock is traded at $0.432, with a volume of 172.31K. It is down -7.22% in the last 24 hours and down -32.38% over the past month. Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Previous Close:

$0.4656

Open:

$0.4601

24h Volume:

172.31K

Relative Volume:

0.11

Market Cap:

$6.00M

Revenue:

$19.57M

Net Income/Loss:

$-25.12M

P/E Ratio:

-0.1869

EPS:

-2.3114

Net Cash Flow:

$-19.71M

1W Performance:

-4.68%

1M Performance:

-32.38%

6M Performance:

-79.03%

1Y Performance:

-93.52%

1-Day Range:

$0.4302

$0.4605

1-Week Range:

$0.4302

$0.4835

52-Week Range:

$0.383

$7.95

Vivos Therapeutics Inc Stock (VVOS) Company Profile

Name

Vivos Therapeutics Inc

Sector

Healthcare (1096)

Industry

Medical Devices (140)

Phone

(866)908-4867

Address

7921 SOUTHPARK PLAZA,, LITTLETON

Employee

268

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

VVOS's Discussions on Twitter

Compare VVOS vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VVOS Vivos Therapeutics Inc	0.432	6.00M	19.57M	-25.12M	-19.71M	-2.3114
ABT Abbott Laboratories	93.93	163.61B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	126.42B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	107.36B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.54B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	53.09B	6.30B	1.07B	1.09B	1.8406

Vivos Therapeutics Inc Stock (VVOS) Latest News

Jul 09, 2026

Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView

Jul 09, 2026

Vivos Therapeutics (VVOS) Slides 6.87% as Bearish Pressure Tests Critical SupportCovered Call Trade - dars.gov.et

Jul 09, 2026

Jul 07, 2026

Vivos Therapeutics Announces Securities Purchase Agreement and Registration Rights for PIPE Financing - Minichart

Jul 07, 2026

Vivos Therapeutics Creates New Series A Preferred Stock - TipRanks

Jul 07, 2026

Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital - TradingView

Jul 07, 2026

Vivos Therapeutics (VVOS) completes $2.1M PIPE with preferred stock and warrants - Stock Titan

Jul 07, 2026

Jul 06, 2026

Enterprise value to EBITDA forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView

Jul 06, 2026

Jul 05, 2026

VVOSVivos Therapeutics Inc Latest SEC Filings - Finviz

Jul 05, 2026

Jul 03, 2026

Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance

Jul 03, 2026

Jun 30, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Jun 30, 2026

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants - The Manila Times

Jun 30, 2026

Vivos says its Vida appliance improved insomnia in all 37 patients - Stock Titan

Jun 30, 2026

Jun 29, 2026

Vivos Therapeutics, Inc. announced that it has received $1 million in funding - marketscreener.com

Jun 29, 2026

Jun 26, 2026

Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact - Stock Titan

Jun 25, 2026

Vivos Therapeutics Enters Debt-for-Equity Deal, Extends $2.6M Financing Deadline With Streeterville - TradingView

Jun 25, 2026

VVOS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026